In the combined safety data set , the incidence of amyloid-related imaging abnormalities with edema or hemorrhage was 0.9 % with solanezumab and 0.4 % with placebo for edema ( P = 0.27 ) and 4.9 % and 5.6 % , respectively , for hemorrhage ( P = 0.49 ) .